Hematological disorders in children pathogenesis and treatment /

This book describes the pathogenesis and treatment of several representative hematological disorders in children, with a special focus on genetic and molecular aspects. Research on the pathogenesis of hematological disorders in children has made remarkable strides; especially molecular target therap...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Ishii, Eiichi (Of Ehime Daigaku) (Editor)
Format: eBook
Language:English
Published: Singapore : Springer, 2017.
Physical Description:
1 online resource.
Subjects:
Pediatric hematology.
Blood -- Diseases.
Children.
Electronic book.
Online Access:SpringerLink - Click here for access
Contents:
  • Preface; Contents; Part I: Hematopoiesis; Chapter 1: Hematopoietic Stem Cells: The Basis of Normal and Malignant Hematopoiesis; 1.1 Introduction; 1.2 Hematopoietic Stem Cells in Normal Hematopoiesis; 1.2.1 Shifting Site of Hematopoiesis; 1.2.2 Identification of HSCs; 1.2.3 Transcriptional Control of HSCs: Hematopoietic Hierarchies and Lineage Determination; 1.2.4 Microenvironment of HSCs: The Niche; 1.3 Stem Cells in Abnormal Hematopoiesis; 1.3.1 Disruption of Transcription Network Leads to Hematopoietic Malignancy; 1.3.2 Cancer Stem Cells and Xenograft Transplantation Models.
  • 1.3.3 Preleukemic Stem Cells as the Reservoir of LSCs1.3.4 In Utero Generation of Pre-LSCs/LSCs in Childhood Leukemia; 1.3.5 Genetic Profiles of Leukemic Stem Cells and Their Progeny; 1.3.6 Clonal Evolution of Preleukemic Cells to Leukemic Stem Cells; 1.4 Characteristics of Leukemic Stem Cells; 1.4.1 Leukemic Stem Cells in AML; 1.4.2 Leukemic Stem Cells in Acute Lymphoid Leukemia (ALL); 1.4.3 Clinical Implications and Future Directions; References; Part II: White Blood Cell Disorders; Chapter 2: Acute Lymphoblastic Leukemia; 2.1 Introduction; 2.2 Epidemiology; 2.3 Pathobiology.
  • 2.3.1 Aneuploidy2.3.1.1 Hyperdiploidy; 2.3.1.2 Hypodiploidy; 2.3.2 Structural Chromosomal Abnormalities; 2.3.2.1 ETV6-RUNX1 (TEL-AML1); 2.3.2.2 TCF3-PBX1 (E2A-PBX1); 2.3.2.3 KMT2A (MLL) Gene Rearrangements; 2.3.2.4 BCR-ABL1; 2.3.2.5 Philadelphia (Ph)-like ALL; 2.3.2.6 iAMP21; 2.3.2.7 IKZF1, CRLF2, and JAK; 2.3.2.8 ETP-ALL; 2.3.2.9 Genetic Alterations at Relapse; 2.4 Clinical Management; 2.4.1 Clinical Presentation; 2.4.2 Diagnostic Procedures; 2.4.3 Treatment; 2.4.3.1 Prognostic Factors; Clinical Features at Initial Diagnosis; Biologic and Genetic Features; Early Treatment Response.
  • 2.4.3.2 Chemotherapy for ALL Remission-Induction Therapy; Consolidation Therapy; Maintenance Therapy; 2.4.3.3 CNS-Directed Therapy; 2.4.3.4 Hematopoietic Stem Cell Transplantation; 2.4.3.5 Special Subcategories; Down Syndrome ALL; Adolescent and Young Adults with ALL; 2.5 Future Challenges; References; Chapter 3: Acute Myeloid Leukemia; 3.1 Introduction; 3.2 Diagnosis of Acute Myeloid Leukemia; 3.3 Treatment of De Novo AML; 3.3.1 Prognostic Factors; 3.3.1.1 Biologic and Genetic Features; 3.3.1.2 Early Treatment Response; 3.3.2 AML Therapy; 3.3.2.1 Remission-Induction Phase.
  • 3.3.2.2 Post-Remission Phase3.3.3 Novel Therapeutic Approach for AML; 3.4 Myeloid Leukemia Associated with Down Syndrome; 3.5 Acute Promyelocytic Leukemia; References; Chapter 4: Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML); 4.1 Introduction; 4.2 Pediatric MDS; 4.2.1 Epidemiology; 4.2.2 Classification; 4.2.3 Clinical and Laboratory Characteristics; 4.2.4 Morphology and Histology; 4.2.5 Cytogenetics; 4.2.6 Pathobiology; 4.2.7 Differential Diagnosis; 4.2.8 Management and Treatment; 4.3 Juvenile Myelomonocytic Leukemia; 4.3.1 Epidemiology; 4.3.2 Classification.

Similar Items